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ABSTRACT 
Aims: The objectives of the present study were to describe smoking prevalence and compare 
the smoking attributes of adult smokers according to the type of tobacco product consumed. 
Methods: Repeated cross-sectional surveys (2004-2005 and 2011-2012) of a representative 
sample of the adult (≥16 years) population in Barcelona, Spain, were used to assess self-
reported tobacco consumption, smoking attributes, and salivary cotinine concentration. The 
survey conducted in 2004-2005 included information on 1,245 subjects and the survey in 2011-
2012 on 1,307 individuals. 
Results: Smoking prevalence decreased over the study period (from 26.6% to 24.1% in self-
reported daily smokers). The prevalence of daily smokers who reported the use of manufactured 
cigarettes declined from 23.7% in 2004-2005 to 17.3% in 2011-2012. The prevalence of roll-
your-own cigarette users increased from 0.4% to 3.7%. According to data obtained in 2011-
2012, the proportion of self-reported roll-your-own cigarette users was higher among men 
(19.8% vs. 9.5% of women), participants aged 16-44 years (22.9% vs. 5.8% of participants aged 
45-65 years and 4.0% of participants aged ≥65 years), and participants with secondary and 
university education (17.7% and 18.5% vs. 7.9% of participants with less than primary and 
primary education). We did not observe differences in cotinine concentrations according to the 
type of tobacco product consumed. 
Conclusions: Systematic collection of data on smoking prevalence and smoker attributes from 
representative samples of the population is necessary for policymakers to develop efficient 
tobacco control interventions. Considering the increase among roll-your-own cigarette users and 
the unclear health consequences of their use, policymakers should aim to implement tax policies 
to equalize the prices of different types of tobacco products.   
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Tobacco kills approximately 6 million people and causes more than half a trillion dollars of 
economic damage each year [1]. In Spain, smoking-related deaths among individuals aged ≥ 35 
years accounts for 14.7% of total mortality (25.1% in men and 3.4% in women) [2]. 
There is strong evidence that tobacco control policies promoted by the WHO Framework 
Convention on Tobacco Control (FCTC), when implemented in an integrated way, reduce the 
prevalence of smoking[3,4]. In Spain, smoking prevalence rates from 1940 through 2007 
showed a decrease after 1980 for men (from 58.5% in 1980 to 31.7% in 2007) and after 2000 
for women (from 26.7% in 2000 to 21.9% in 2007) [5]. The prevalence rate was 23% in Spain 
in 2014 (27.6% for men and 18.6% for women) [6]. 
Regulations implemented in recent years have not been shown to have a direct effect on tobacco 
consumption, and the decline in smoking prevalence and the number of cigarettes consumed 
describe a continuation of the short- and medium-term temporal evolution observed prior to the 
introduction of smoke-free legislation [7,8]. 
Stepwise smoke-free legislation has been implemented in Spain in the last decade. Law 
28/2005, which passed January 1, 2006, banned smoking in all public and work places, with 
some exceptions in hospitality venues [9]. Law 42/2010 came into force January 2, 2011, 
extending the smoking ban to all hospitality venues without exception (bars, cafes, pubs, 
restaurants, discos, and casinos), including some outdoors areas [10].  
In the same time period when the tobacco smoke-free laws were implemented, Spain suffered 
an economic crisis that seems to have favored an increase in the consumption of other tobacco 
products subject to lower taxes, making them cheaper alternatives for smokers [11,12]. 
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The objective of this study was to describe smoking prevalence and to compare smoker 
attributes according to the type of tobacco product consumed in the Spanish adult population 
based on self-reported data and the levels of salivary cotinine in two time periods: 2004-2005 
and 2011-2012, before and after smoke-free legislation. 
METHODS 
Study design and selection of study participants 
This study had a repeated cross-sectional design. We included a representative, random sample 
by age, sex, and district of the population of Barcelona, Spain. Surveys were conducted before 
and after the implementation of smoke-free legislation. Pre-legislation data were obtained 
between March 2004 and December 2005. We used the same strategy to collect post-legislation 
data between June 2011 and March 2012. We selected participants from the official 2001 
(participants in the pre-legislation survey) and 2010 (participants in the post-legislation survey) 
population census of Barcelona, a reliable source of population based information. Detailed 
information about the pre-legislation survey  was provided in previous studies [13-15]. 
Briefly, for each survey we determined a sample size of 1,560 people with standard procedures 
( error 5%, beta error 20%, and 20% loss for independent samples). The survey conducted in 
2004-2005 included a final sample of 1,245 individuals and the survey conducted in 2011-2012 
included a final sample of 1,307 individuals. These sample sizes were sufficient to detect a 40% 
difference in salivary cotinine concentrations between the two surveys.  
We obtained data and addresses for Barcelona residents from the city census (years 2001 and 
2010). Individuals aged 16 years and older were eligible to participate in this study. A letter was 
mailed to eligible individuals to describe the purpose of the study and to inform them that they 
had been selected at random. Participants that could not be located after several attempts (at 
different times of the day and different days of the week) and those that declined to participate 
in the study were replaced at random. The replacements were chosen from eligible individuals 
of the same sex, within a 5-year age group, and within the same district of residence. 
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Substitutions accounted for 50.7% and 54.6% of the 2004-2005 and 2011-2012 surveys, 
respectively. Individuals who agreed to participate were interviewed at home by trained 
interviewers. Participants were asked to sign an informed consent form before proceeding with 
the face-to-face interview. The same questionnaire was used in both surveys (on traditional 
paper in the 2004-2005 survey and in computer-assisted form in the 2011-2012 survey). 
Additional questions were included in the second survey regarding smoke-free legislation. After 
completing the questionnaire, respondents were asked to provide a sample of saliva for the 
cotinine analysis. The Research and Ethics Committee of Bellvitge University Hospital 
approved the study protocols and informed consent forms.  
 
Self-reported tobacco consumption and smoking characteristics 
Self-reported smoking behavior was determined with the question, “Which of the following 
statements describes your behavior relative to tobacco?” Daily smokers were defined as 
individuals who, at the time of the interview, reported that they smoke at least one cigarette per 
day; occasional smokers as individuals who, at the time of the interview, reported that they 
smoke occasionally; former smokers as individuals who, at the time of the interview, reported 
that they did not smoke currently but had smoked at least one cigarette per day or occasionally 
in the past; and never smokers were those who declared that they had never smoked. Self-
reported non-smokers (never and former) who had a salivary cotinine concentration > 10 ng/mL 
were considered missing data because they had cotinine concentrations consistent with active 
smoking [16] and we did not collect the smoking-related information. 
For daily smokers, detailed information was collected on  smoking characteristics: cigarettes 
smoked per day (CPD), age when they started smoking, number of cigarettes smoked during the 
previous 24 and 48 hours, brand of cigarettes smoked most often, type of tobacco product 
smoked (manufactured cigarettes, roll-your-own cigarettes, cigars, small cigars (puritos), pipes, 
or other tobacco), use of filter tips, depth and frequency of inhalation, and use of nicotine gum 
or patches for smoking cessation.  
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We collected information on nicotine dependence using the Fagerström Test for Cigarette 
Dependence (FTCD) [17-19]. Based on the FTCD scores (range 0–10 points), we classified 
subjects according to their nicotine dependence (0–4, low; 5, medium; 6–10, high). 
Finally, we registered the stage of change based on the Prochaska and DiClemente algorithm 
[20]. We considered three smoking stages of change: precontemplation, smokers that were not 
seriously considering quitting within the next 6 months; contemplation, smokers that were 
seriously considering quitting within the next 6 months but not within the next 30 days, or 
smokers that had not attempted to quit for at least 24 hours in the past year, or both; and 
preparation, smokers that were planning to quit within the next 30 days and had attempted to 
quit for at least 24 hours in the past year [21,22]. In the present study we focused on current 
daily smokers; therefore, we did not consider the other two stages, action (those who had quit 
during the past 6 months) and maintenance (those who had quit for more than 6 months). 
 
Sociodemographic covariates 
The sociodemographic covariates were sex, age (categorised into three age-groups: 16–44 years, 
45–64 years, and ≥65 years old), and educational level categorized in three groups as “Less than 
primary and primary education” (illiterate subjects, subjects with uncompleted elementary 
education, and subjects with complete primary education); “Secondary  education” (subjects 
with compulsory secondary education and/or voluntary high school, or vocational training); and 
'University education' (subjects with University degree or postgraduate studies). 
 
Salivary cotinine 
We asked the participants to provide a saliva sample to determine the cotinine levels. Cotinine 
is the main metabolite of nicotine and a stable, specific, and sensitive biomarker of tobacco 
consumption [23]. We followed the same protocol in both surveys for collecting the saliva 
sample, as explained previously [15]. Cotinine analysis was performed in the laboratory of the 
IMIM-Hospital Research Institute in Barcelona. The limit of quantification was 0.1 ng/mL, the 





We calculated prevalence rates to characterize smoking behavior for the period studied among 
the population. For current daily smokers we computed the proportion of tobacco products 
consumed in 2004-2005 and in 2011-2012. The results were stratified by sex, age, and 
education level. For continuous variables, except cotinine, we computed the mean and standard 
deviation (SD). For cotinine concentrations, we used geometric means (GMs) and geometric 
standard deviations (GSDs) due to a skewed distribution. We compared smoking attributes for 
daily smokers according to the type of tobacco consumed using the data obtained in 2011-2012. 
We used relative frequencies (%) for categorical variables and mean and SD for numerical data. 
We also computed the GM and GSD to describe the cotinine concentrations among current 
daily smokers of manufactured cigarettes only and roll-your-own cigarettes only and stratified 
by sociodemographic and other smoking attributes. Samples with cotinine concentrations below 
the limit of quantification were assigned a value of 0.05 ng/mL (half the limit of quantification). 
Statistical analyses were performed in SPSS v17.0 and Stata 10.  
 
RESULTS 
Sample and smoking prevalence 
We had information on 2,552 participants: 1,245 subjects in the pre-legislation survey and 1,307 
in the post-legislation survey. The samples were similar in regards to the proportions of men 
and women, but we found significant differences in age and education level. Nineteen 
participants in the pre-legislation survey were excluded because they were <16 years old. Of the 
self-reported non-smokers (former and never smokers), 110 (62 in the pre-legislation and 48 in 
the post-legislation surveys) were not included in this analysis because they did not provide a 
saliva sample. In addition, 12 (10 in the pre-legislation and 2 in the post-legislation survey) 
were excluded because cotinine analysis was not possible (i.e., insufficient sample). A total of 
83 non-smokers from the pre-legislation survey and 19 from the post-legislation survey were 
excluded because they had cotinine concentrations consistent with active smoking (>10 ng/mL). 
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Therefore, the final sample for analysis included a total of 1,071 participants before the 
legislation and 1,238 participants after the legislation. 
Smoking prevalence decreased over the period 2004-2005 and the period 2011-2012: from 
26.6% (95%CI 24.0-29.2) to 24.1% (95%CI 21.7-26.5) in daily smokers, and from 5.8% 
(95%CI 5.5-6.1) to 5.0% (95%CI 4.7-5.3) in occasional smokers (Fig. 1). Self-reported former 
smokers represented 27.7% (95%CI 25.0-30.4) of participants in 2004-2005 and 26.8% (95%CI 
24.3-29.3) of participants in 2011-2012. As shown in Fig. 1, none of these changes were 
significant. 
[Fig 1 about here] 
 
The prevalence of daily smokers fell from 32.5% (95%CI 28.3-36.7) to 29.4% (95%CI 25.7-
33.1) among men and from 21.7% (95%CI 18.4-25.0) to 19.3% (95%CI 16.3-22.3) among 
women. The decline in smoking prevalence among daily smokers between 2004-2005 and 
2011-2012 was higher among participants aged 16-44 years (from 36.4%, 95%CI 31.8-41.0, to 
29.4%, 95%CI 25.7-33.1) with substantial changes in the prevalence of daily smokers among 
participants aged 45-64 years and ≥65 years. When comparing by education level, we observed 
the highest decrease among participants with secondary education (from 38.9%, 95%CI 32.9-
44.9, to 26.1%, 95%CI 22.2-30.0), followed by participants with university education (from 
24.3%, 95%CI 19.9-28.7, to 22.00%, 95%CI 18.0-26.0). The prevalence of daily smokers with 
less than primary and primary education increased from 21.3% (95%CI 17.5-25.1) to 23.8% 
(95%CI 19.1-28.5). 
 
Type of tobacco consumed among daily smokers 
Fig. 2 shows the prevalence of self-reported daily smokers according to the type of tobacco 
product smoked. The prevalence of smokers who reported using manufactured cigarettes (only 
or combined with other types of tobacco products different from roll-your-own cigarettes) 
declined from 23.7% (95%CI 21.2-26.2) in 2004-2005 to 17.3% (95%CI 15.2-19.4) in 2011-
2012. Roll-your-own cigarette users (only or combined with other types of tobacco products 
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different from manufactured cigarettes) significantly increased from 0.4% (95%CI 0.02-0.8) to 
3.7% (95%CI 2.6-4.8), and users of both manufactured cigarettes and roll-your-own cigarettes 
(with or without other types of tobacco products) increased from 0.9% (95%CI 0.3-1.5) to 1.7% 
(95%CI 1.0-2.4).  
[Fig 2 about here] 
 
Table 1 shows the percent distribution (overall and stratified by socio-demographic 
characteristics) of self-reported daily smokers according to the type of tobacco product 
consumed (same categories as in Fig. 2) before and after the legislation. We observed a 
significant increase in roll-your-own users among both men and women and among participants 
aged 16-44 years (Table 1). Roll-your-own was also more prevalent among participants with 
secondary and higher education (Table 1), and this association was modified by age. The 
stratified analysis by age showed roll-your-own use was more frequent among smokers aged 16-
44 years (less than primary and primary: 16.1%, secondary: 23.8%, university: 25.5%) as 
compared to those ≥45 years (2.2%, 6.5%, and 8.1%, respectively).  We observed the same 
pattern among participants aged 45-65 and ≥65 years and participants with less than primary 
and primary education, but the differences were not significant. According to data obtained in 
2011-2012, the proportion of self-reported roll-your-own cigarette users was higher among men 
than women (19.8% vs. 9.5%), participants aged 16-44 years (22.9% vs. 5.8% among 
participants aged 45-65 years and 4.0% among participants ≥65 years), and among participants 
with secondary and university education compared to participants with less than primary and 
primary education (17.7% and 18.5% vs. 7.9%, respectively). 
[Table 1 about here] 
 
Smoking attributes among daily smokers in 2011-12 according to the use of manufactured and 
roll-your-own cigarettes 
We analyzed the smoking attributes of daily smokers obtained in the 2011-12 survey according 
to the use of manufactured and roll-your-own cigarettes (manufactured cigarettes only, roll-
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your-own cigarettes only, and both manufactured and roll-your-own only; n=260). From these 
smokers, we excluded 58 participants for different reasons (see footnote to Table 2); therefore, 
we finally included 202 participants in the analysis. Manufactured cigarette users reported the 
highest nicotine dependence levels (45.6% vs. 39.1% among roll-your-own cigarette users and 
14.3% among users of both types of tobacco products) with no significant differences 
(p=0.151). The majority of smokers were precontemplators, independent of the tobacco product 
smoked (74.5% among manufactured cigarettes users, 87.5% among roll-your-own cigarette 
users and 70.0% among users of both types of tobacco products). More manufactured cigarette 
users were in the contemplation stage compared to roll-your-own and both manufactured and 
roll-your-own cigarette users. No roll-your-own cigarette users were in the preparation stage of 
change. More roll-your-own cigarette users reported smoking ≤10 CPD compared to 
manufactured cigarette users and users of both manufactured and roll-your-own cigarettes, who 
mostly reported between 11 and 20 CPD (Table 2).  
We did not observe significant differences in the mean FTCD scores, the mean CPD, or the 
frequency and depth of inhalation according to the tobacco product smoked. 
[Table 2 about here] 
 
Table 3 shows the cotinine levels in daily smokers from the 2011-2012 survey stratified by 
socio-demographic and smoking attributes according to the use of manufactured cigarettes only 
and roll-your-own cigarettes only (n=192). Overall, the GM salivary concentration was 186.77 
ng/mL among those who used roll-your-own cigarettes only and 185.05 ng/mL among those 
who used manufactured cigarettes only, with no significant differences between them 
(p=0.778). We did not observe differences in cotinine concentrations according to the type of 
tobacco product smoked when we stratified by socio-demographic characteristics and different 
smoking attributes, except for smokers with medium dependence and smokers of 11-20 CPD, 





Our results showed a nonsignificant reduction in smoking prevalence over the period 2004-2005 
and the period 2011-2012 from 26.6%  to 24.1% in daily smokers. Similar to our results, 
another study conducted in Spain with national data showed a nonsignificant decrease from 
23.4% in 2006 to 20.7% in 2011 [24]. A study conducted in Galicia, Spain, found a decrease in 
the prevalence of tobacco consuption from 25.4% in 2007 to 21.8% in 2015 [25].  
We observed a relative reduction in the smoking prevalence of 9.5% among men who smoke 
daily and 11.1% among women who smoke daily in the period between 2004-2005 and 2011-
2012. The highest relative reduction in smoking prevalence was observed among participants 
aged 16-44 years (-19.2%) and among participants with secondary and university education. 
During this period, two tobacco smoke-free policies were implemented in Spain (Law 28/2005 
and Law 42/2010). However, we did not take into account previous temporal trends. One study 
conducted in England to examine the impact of the legislation on smoking prevalence 
controlling for secular trends through the end of 2008 observed a reduction in smoking 
prevalence from 25% in 2003 to 21% in 2008. In this study, however, after taking  into account 
the previous temporal, the implementation of smoke-free legislation was not associated with a 
significant change in smoking prevalence [26].  
Our results indicate an important reduction in the prevalence of manufactured cigarette users in 
2011-2012 compared to 2004-2005. In contrast, both roll-your-own cigarette users and mixed 
manufactured and roll-your-own cigarette users considerably increased. This data makes sense 
with the decrease in the sales of manufactured cigarettes per capita jointly with an increase in 
roll-your-own cigarette sales in Spain [11]. Among daily smokers, roll-your-own cigarette users 
(only or combined with other types of tobacco products different from manufactured cigarettes) 
represented 15.4% of total smokers in 2011-2012. A survey conducted in Galicia, Spain, found 
an increase in the consumption of roll-your-own tobacco from 1.8% in 2007 to 18.6% in 2015 
[25]. These percentages observed in Spain are higher than the percentage reported in a similar 
study conducted in Italy in 2011 and 2012, in which 4.6% of smokers reported to smoke roll-
your-own cigarettes most frequently [27], and higher than the 6.7% of smokers in the US who 
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smoke roll-your-own cigarettes only [28]. A study conducted in different countries within 
Europe showed that among current smokers, users of only roll-your-own cigarettes represented 
8.4% of the whole sample [29]. Another study found that the prevalence of smokers using only 
roll-your-own cigarettes was 28.4% in the UK, 24.3% in Australia, and 17.1% in Canada, 
higher than our results [28].  
The increase in roll-your-own tobacco users for the period studied is remarkable for both men 
and women, and those aged 16-44 years. We observed also an increase in roll-your-own tobacco 
users among people with secondary and university education, specially those aged 16-44 years. 
The increase in smokers of  manufactured cigarettes combined with roll-your-own cigarettes 
was higher among women than men, and among  people aged 16 to 44. According to the data 
obtained in 2011-2012, we could define the pattern of roll-your-own cigarette users as men, 
people aged 16-44 years, and people with a higher education level. This pattern is the same as 
that obtained in other studies focusing on the attributes of roll-your-own cigarette smokers 
[27,28].  
Previous studies including data obtained from the ITC study in Australia, Canada, the UK, and 
the US found that roll-your-own cigarette users have a higher level of nicotine addiction than 
manufactured cigarette users [28]. Our results indicate no significant differences in nicotine 
dependence according to the type of tobacco product smoked, though the percentage of daily 
smokers with low nicotine dependence was higher among roll-your-own cigarette users than 
other types of tobacco products smoked. Similar to the ITC study [28] and another study 
conducted with in Europe [29], we found that roll-your-own cigarette users were more likely to 
be in the precontemplation stage of change, and our results indicated that none of them were in 
the preparation stage. Finally, almost all roll-your-own cigarette users reported smoking ≤ 20 
CPD with only 7.4% of this group being heavy smokers (>20 CPD). In agreement to  the ICT 
study results [28], we also found that the depth of inhalation among both roll-your-own and 
mixed manufactured and roll-your-own cigarette smokers was deeper than among manufactured 
cigarette smokers, though the difference was not significant. According to the smoking 
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attributes, we could describe the roll-your-own cigarette users as smokers with mainly low 
dependence on nicotine and no intention to quit, as they claim to smoke a few to a moderate 
number of cigarettes a day and to inhale more deeply than manufactured cigarette smokers. 
These smoking patterns among roll-your-own cigarette users and considering they are mainly 
young people, would make sense with the broad but false belief that roll-your-own tobacco is 
less harmful than other forms of tobacco, as well as a more positive perception of tobacco use 
and the satisfactory feeling they produced [28,30]. 
Contrary to the general belief that roll-your-own cigarettes  users are less exposed to the 
harmful effects than manufactured cigarette users [28], we found that roll-your-own cigarette 
users have similar cotinine levels as manufactured cigarette users. Furthermore, these cotinine 
levels were similar for smokers with the same smoking characteristics (FTCD scores, stages of 
change, and depth and frequency of inhalation). These findings could be explained by people 
regulating their intake of nicotine to reach the desired doses [31]. An additional explaination 
could be that nicotine content of roll-your-own cigarettes is higher than in manufactured 
cigarettes [31,32] and hence eventhough roll-your-own users smoke less cigarettes per day they 
have similar cotinine levels to manufactured cigarette users.  
Public Heath Implication 
Increases of cigarette prices are associated to decreasing smoking prevalence and number of 
CPD smoked [33-35]. In Spain, the government has strengthened tobacco policies, including 
regulations on tobacco taxes. However, these changes have mainly affected manufactured 
cigarettes, whereas other tobacco products have had less of an increase in taxation and become a 
cheaper alternative for smokers [12]. Thus, it is not rare to observe such an increase in the 
proportion of self-reported roll-your-own cigarette users, especially among young and middle-
aged people, and considering the collateral effects of the current economic crisis in Spain.  
Economic crisis may affect smoking behaviour, but current research provides discrepant results. 
In the last decades of XX century in the US, periods of economic recessions led to a decrease in 
15 
 
the smoking prevalence [36] whilst in Italy the smoking prevalence increased in 2009 compared 
with 2008 possibly due to the economic crisis [37].Some population groups (ie, poor, young 
people) may react in two different ways to economical crisis. Some smokers may decide to quit 
or reduce their consumption for affordability reasons [38]. In our data, the prevalence of 
smoking reduced but did not significantly change during the study period. Other groups may 
react by shifting to cheaper brands or to cheaper forms of tobacco. The cheaper prices of roll-
your-own cigarettes have been reported to be the main reason why smokers switch from 
manufactured cigarettes to roll-your-own cigarettes [30].  
Economics is not the only reason to switch from manufactured cigarettes to roll-your-own 
cigarettes. Some smokers enjoy the ritual of rolling a cigarette, whereas others think roll-your-
own cigarettes are more satisfying and taste better [28]. In addition, some smokers think that 
rolled cigarettes reduce the amount of smoke, contain fewer additives and are safer [28,30]. 
However, rolling tobacco yields higher nicotine, tar, and carbon monoxide levels than 
manufactured cigarettes [28,32,39,40]. These reasons mimic the arguments raised several 
decades ago to favor the use of “less harmful cigarettes” under the mask of low tar and light 
brands [32].   
Limitations and strengths of this study 
One potential limitation of the study is information bias derived from the use of a questionnaire 
to obtain the information. However, we could validate our results on smoking status with 
salivary cotinine measurements and by excluding self-reported non-smokers with high cotinine 
concentrations, avoiding misclassification. Another potential limitation derives from the use of 
the limit of 35 ng/mL of cotinine per one cigarette smoked, as the boundary above which a level 
would be considered not biologically plausible in relation to the self-reported consumption for 
roll-your-own and mixed roll-your-own and manufactured cigarette users [31]. However, this 
limit was obtained in experimental studies with manufactured cigarettes and could be different 
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for roll-your-own cigarette smokers. To the best of our knowledge, no data on this topic have 
been published for roll-your-own cigarettes.  
This study included representative, random samples of the population of Barcelona, Spain. 
Although both samples were representative from the target population, some changes in the 
population with regard to age and education occurred across time. Since the crude estimates are 
reliable and informative, we opted to present them together with the data in strata of sex, age, 
and education. This study is the first to systematically evaluate smoking prevalence and smoker 
attributes before and after the implementation of smoke-free legislation, using cotinine as a 
biological marker of tobacco consumption, and  focusing on manufactured and roll-your-own 
cigarette users in Spain. Moreover, to the best of our knowledge, this study is the first that 
considers cotinine levels among smokers according to the type of tobacco product smoked.  
Conclusions 
It is necessary to systematically collect data on smoking prevalence and smoking attributes, 
including types of tobacco product consumed, from representative samples of the population for 
policymakers to develop efficient tobacco control interventions and recommendations for the 
population. Considering such an increase among roll-your-own cigarette users and the unclear 
consequences of their use on health, policymakers should aim to implement tax policies to 
equalize the prices of different types of tobacco products. Moreover, further research is needed 
to determine exposure to tobacco biomarkers and the health effects of using roll-your-own 
cigarettes. Specific tobacco control strategies should be developed to tackle roll-your-own 
cigarette smoking, as this emerging type of tobacco consumption is targeting young people. 
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Figure 2.  Prevalence of daily smokers among the adult population of Barcelona, Spain (2004-
05 and 2011-12), according to the type of tobacco consumed. 
 
 
Footnote to Figure 2. 
Manufactured cigarettes refers to exclusive use of manufactured cigarettes  or combined with 
other tobacco products including cigars, small cigars (puritos), pipes, or other tobacco different 
from roll-your-own cigarettes. 
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Roll-your-own cigarettes  refers to exclusive use of roll-your-own cigarettes or combined with 
other tobacco products including cigars, small cigars (puritos), pipes, or other tobacco different 
from manufactured cigarettes. 
Mixed use refers to manufactured and roll-your-own cigarettes combined use (exclusive use of 
both types or combined with other types of tobacco products). 
Other types refers to exclusive use of tobacco products (cigars, small cigars (puritos), pipes, or 
other tobacco) other than manufactured and roll-your-own cigarettes.
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Other types (%) 
 
 2004-05 2011-12 2004-05 2011-12 2004-05 2011-12 2004-05 2011-12 2004-05 2011-12 p-value 
Overall 285 298 89.1 71.8 1.4 15.4 3.5 7.0 6.0 5.7 <0.001 
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*This association was modified by age (see Results text).
            Sex            
Men  158 172 82.9 64.0 1.9 19.8 5.1 6.4 10.1 9.9 <0.001 
Women  127 126 96.9 82.5 0.8 9.5 1.6 7.9 0.8 0.0 0.001 
            Age (years)            
16-44 156 170 91.0 62.9 1.3 22.9 5.1 11.8 2.6 2.4 <0.001 
45-64 102 103 90.2 85.4 2.0 5.8 2.0 1.0 5.9 7.8 0.440 
≥65 27 25 74.1 76.0 0.0 4.0 - - 25.9 20.0 0.526 




96 76 89.6 82.9 2.1 7.9 2.1 5.3 6.3 3.9 0.175 
Secondary 98 130 89.8 66.2 1.0 17.7 6.1 11.5 3.1 4.6 <0.001 * 
University 89 92 87.6 70.7 1.1 18.5 2.2 2.2 9.0 8.7 0.002 * 
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Footnote to Table 1. 
Manufactured cigarettes refers to exclusive use of manufactured cigarettes  or combined 
with other tobacco products including cigars, small cigars (puritos), pipes, or other tobacco 
different from roll-your-own cigarettes. 
Roll-your-own cigarettes  refers to exclusive use of roll-your-own cigarettes or combined 
with other tobacco products including cigars, small cigars (puritos), pipes, or other tobacco 
different from manufactured cigarettes. 
Mixed use refers to manufactured and roll-your-own cigarettes combined use (exclusive 
use of both types or combined with other types of tobacco products). 
Other types refers to exclusive use of tobacco products (cigars, small cigars (puritos), 





















Table 2.  Smoking attributes of adult daily smokers (manufactured vs roll-your-own) in 
Barcelona, Spain (2011-12) 
Note: We excluded six participants using nicotine gum or nicotine patch for cessation and 18 
participants who did not provide a saliva specimen or for whom cotinine determination was 
not possible. An additional 34 people were excluded because their cotinine concentrations 











Overall (N) 165 27 10  
     
Nicotine dependence level (%)    0.151 
Low 40.3 52.2 42.9  
Medium  14.1 8.7 42.9  
High  45.6 39.1 14.3  
     
Stages of change (%)    0.023 
Precontemplation  74.5 87.5 70.0  
Contemplation  22.8 12.5 10.0  
Preparation  2.8 - 20.0  
     
Time to first cigarette (%)    0.501 
>60 min  28.5 23.1 40.0  
31-60 min  14.5 26.9 20.0  
6-30 min  35.2 30.8 40.0  
≤5 min  21.8 19.2 -  
     
Cigarettes per day (CPD) (%)    0.046 
≤10 32.7 51.9 -  
11-20 52.1 40.7 70.0  
21-30 10.3 7.4 30.0  
>30 4.8 - -  
     
Frequency of inhalation (%)     0.549 
All the time 22.6 18.5 10.0  
Half the time 66.5 74.1 90.0  
Seldom 11.0 7.4 -  
     
Depth of inhalation (%)    0.515 
Light 8.0 3.7 10.0  
Moderate 39.3 29.6 20.0  
Deep 52.8 66.7 70.0  
     
Overall FTCD score, mean (SD) 5.10 (2.22) 4.70 (1.96) 4.57 (1.40) 0.659 
     
Overall CPD, mean (SD) 15.40 (8.88) 12.28 (6.60) 18.21 (5.35) 0.064 
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Table 3.  Salivary cotinine concentrations in daily smokers in Barcelona, Spain (2011-12), 










































arison between manufactured and roll-your-own and both manufactured and roll-your-own 
cigarette users did not provide any significant differences. 
 Only manufactured Only  roll-your-own   p-value* 
 N GM (GSD) 
ng/mL 
N GM (GSD) 
ng/mL 
 
Overall 165 185.05 (2.20) 27 186.77 (2.35) 0.778 
      Sex      
Men   78 207.06 (2.19) 19 178.07 (2.33) 0.424 
Women  87 167.34 (2.18) 8 209.22 (2.53) 0.376 
      Age (years)      
16-44  80 168.00 (2.24) 22 172.66 (2.50) 0.649 
45-64  72 213.99 (2.04) 4 235.34 (1.48) 0.926 
≥65  13 150.07 (2.66) 1 417.16 0.385 
      Education level      
Less than primary and 
primary  
48 198.61 (2.05) 5 200.26 (2.11) 1.000 
Secondary  65 191.12 (2.33) 12 255.33 (1.77) 0.273 
University  52 166.49 (2.18) 10 123.97 (2.91) 0.455 
      Nicotine dependence level      
Low  60 115.35 (2.11) 12 118.00 (2.64) 0.618 
Medium  21 201.42 (1.97) 2 493.86 (1.27) 0.029 
High  68 279.25 (1.81) 9 269.77 (1.73) 0.800 
      Stage of change      
Precontemplation  108 190.46 (2.35) 21 195.16 (2.49) 0.745 
Contemplation  33 211.11 (1.69) 3 282.10 (1.04) 0.317 
Preparation 4 92.75 (1.45)  - - 
      Time to first cigarette      
>60 min  47 96.41 (2.15) 6 111.89 (2.38) 0.715 
31-60 min  24 173.90 (1.63) 7 129.81 (2.86) 0.777 
6-30 min  58 235.88 (1.93) 8 249.12 (1.88) 0.814 
≤5 min  36 305.56 (1.80) 5 380.28 (1.16) 0.498 
      Cigarettes per day      
≤10 54 90.47 (2.17) 14 105.93 (2.27) 0.339 
11-20 86 245.19 (1.62) 11 346.42 (1.35) 0.015 
21-30 17 292.89 (1.83) 2 331.21 (1.27) 0.690 
>30 8 424.23 (1.31)   - 
      Frequency of inhalation       
All the time 37 200.22 (2.35) 5 191.82 (2.00) 0.771 
Half the time 109 169.51 (2.21) 20 210.81 (2.13) 0.207 
Seldom 18 250.15 (1.58) 2 52.08 (5.21) 0.059 
      Depth of inhalation      
Light 13 144.51 (2.32) 1 280.48  0.264 
Moderate 64 181.05 (2.29) 8 93.80 (2.84) 0.058 
Deep 86 193.02 (2.11) 18 247.97 (1.81) 0.192 
